Mitroflow DL Post Approval Study- North America
Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment Post Approval Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Medical Center
-
San Diego, California, United States, 92123
- Sharp Memorial Hospital
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- River City Clinical Research
-
Jacksonville, Florida, United States, 32209
- UF Health - Jacksonville
-
Lakeland, Florida, United States, 33805
- Watson Clinic Center for Research
-
-
Maryland
-
Bethesda, Maryland, United States, 20814
- Suburban Hospital - John Hopkins Medicine
-
-
Michigan
-
Bay City, Michigan, United States, 48708
- Bay Regional Medical Center
-
Detroit, Michigan, United States, 48236
- St. John Hospital & Medical Center
-
-
New Hampshire
-
Manchester, New Hampshire, United States, 03102
- Catholic Medical Center
-
-
New Jersey
-
Paterson, New Jersey, United States, 07503
- St. Joseph's Regional Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, United States, 19096
- Lankenau Medical Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients is indicated for Mitroflow DL implantation according to the Instructions for Use (IFU).
- Patient or patient's legal representative is willing to sign the informed consent.
- Patient's preoperative evaluation indicated the need for native or prosthetic aortic valve replacement
- Any patient amenable to aortic valve replacement with a biological prosthesis should be enrolled in the study, even in conjuction with valve repair, coronary artery bypass grafting and other procedures
- Patient is able to return for all follow-up evaluations for the duration of the study (geographically stable).
Exclusion Criteria:
- Patient is contra-indicated for Mitroflow DL implantation according to the Instructions for Use.
- The patient has a pre-existing valve prosthesis in the mitral, pulmonary, or tricsupid position.
- Patient requires a double or triple valve replacement (repair is not considered an exclusion).
- Patient has active endocarditis or myocarditis.
- Patient is pregnant or lactating.
- Patient is participating in a concomitant research study of an investigational product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Mitroflow DL
Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
|
Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of structural Valve Deterioration in Implanted Patients
Time Frame: 8 years
|
To establish rates of structural valve deterioration through 8 years follow-up
|
8 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Early and Late Valve-Related Adverse Event Rates
Time Frame: Early (30 days) and Late (> 30 days)
|
To determine early and late valve-related adverse event rates, including valve thrombosis, thromboembolism, paravalvular leak (all and major), bleeding(all and major), and endocarditis, for Mitroflow DL are comparable to appropriate historical controls
|
Early (30 days) and Late (> 30 days)
|
|
Early and Late Rates of hemolysis, non-structural valve dysfunction, valve-related embolism, re-operation, explant and death
Time Frame: Early (30 days) and Late (> 30 days)
|
To determine rates of hemolysis, non-structural dysfunction, valve-related embolism, reoperation, explant and death (all cause and valve-related)
|
Early (30 days) and Late (> 30 days)
|
|
Hemodynamic Performance
Time Frame: 8 years
|
To evaluate the hemodynamic performance of the Mitroflow DL valve as compared to other stented aortic bioprostheses in the current literature
|
8 years
|
|
Improvements in NYHA
Time Frame: 8 years
|
To evaluate the overall improvements in patient condition by comparison of pre-operative and post-operative New York Heart Associate (NYHA) functional classification
|
8 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: John Kern, MD, University of Virginia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TMT001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.